Exelixis Inc (EXEL) reported better-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share (EPS) of $0.69, surpassing Wall Street's consensus estimate of $0.63 by $0.06. Revenue remained steady at $0.6 billion, aligning with analyst expectations.
This update provides insight into Exelixis's operational performance and financial health, reflecting its ongoing focus on oncology. The company, headquartered in Alameda, California, is dedicated to discovering and developing new medicines for challenging cancers. It currently employs 1,147 full-time staff and has produced four marketed pharmaceutical products, including cabozantinib, which is approved for multiple cancer indications.
Exelixis will host an earnings conference call after market close to discuss these results and provide further commentary on its business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance and future outlook.
As of November 7, 2025, Exelixis has a market capitalization of $10.77 billion and a trailing twelve-month price-to-earnings (P/E) ratio of 17.88. The company is set to report its next earnings on November 3, 2025, with an EPS estimate of $0.6314 and revenue expectation of $0.6 billion.